title: Modified weekly cisplatin-based chemotherapy is acceptable in postoperative concurrent chemoradiotherapy for locally advanced head and neck cancer.
abstract: BACKGROUND
  Triweekly cisplatin-based postoperative concurrent chemoradiotherapy (CCRT) has high intolerance and toxicities in locally advanced head and neck cancer (LAHNC). We evaluated the effect of a modified weekly cisplatin-based chemotherapy in postoperative CCRT.
  
  
  METHODS
  A total of 117 patients with LAHNC were enrolled between December 2007 and December 2012. Survival, compliance/adverse events, and independent prognostic factors were analyzed.
  
  
  RESULTS
  Median follow-up time was 30.0 (3.1-73.0) months. Most patients completed the entire course of postoperative CCRT (radiotherapy ≥ 60 Gy, 94.9%; ≥ 6 times weekly chemotherapy, 75.2%). Only 17.1% patients required hospital admission. The most common adverse effect was grade 3/4 mucositis (28.2%). No patient died due to protocol-related adverse effects. Multivariate analysis revealed the following independent prognostic factors: oropharyngeal cancer, extracapsular spread, and total radiation dose. Two-year progression-free survival and overall survival rates were 70.9% and 79.5%, respectively.
  
  
  CONCLUSIONS
  Modified weekly cisplatin-based chemotherapy is an acceptable regimen in postoperative CCRT for LAHNC.
authors: Division of Hematology and Oncology, Show Chwan Memorial Hospital, Changhua, Taiwan ; Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Program in Molecular Medicine, School of Life Sciences, National Yang-Ming University, Taipei, Taiwan.
authors: Hsueh-Ju
authors: HJ
authors: Lu
authors: Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Department of Medicine,Taipei City Hospital,Yang-Ming Branch, Taipei, Taiwan.
authors: Chao-Chun
authors: CC
authors: Yang
authors: Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Department of Oncology Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
authors: Ling-Wei
authors: LW
authors: Wang
authors: Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Department of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan.
authors: Pen-Yuan
authors: PY
authors: Chu
authors: Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Department of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan.
authors: Shyh-Kuan
authors: SK
authors: Tai
authors: Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan.
authors: Ming-Huang
authors: MH
authors: Chen
authors: Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan.
authors: Muh-Hwa
authors: MH
authors: Yang
authors: Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan.
authors: Peter Mu-Hsin
authors: PM
authors: Chang
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D059248:Chemoradiotherapy / Q000379:methods; D002945:Cisplatin / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D011184:Postoperative Period; D011379:Prognosis; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin